MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Gilead Sciences Inc.

Suletud

SektorTervishoid

111.03 -0.63

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

110.68

Max

112.85

Põhinäitajad

By Trading Economics

Sissetulek

530M

1.8B

Müük

29M

7.6B

P/E

Sektori keskmine

294.868

63.778

Aktsiakasum

1.9

Dividenditootlus

2.82

Kasumimarginaal

23.557

Töötajad

17,600

EBITDA

-655M

3.1B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+2.93% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

2.82%

2.39%

Järgmine tulemuste avaldamine

24. apr 2025

Järgmine dividendimakse kuupäev

26. juuni 2025

Järgmine aktsia dividendi kuupäev (ex-date)

13. juuni 2025

Turustatistika

By TradingEconomics

Turukapital

18B

140B

Eelmine avamishind

111.66

Eelmine sulgemishind

111.03

Uudiste sentiment

By Acuity

9%

91%

10 / 386 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

Gilead Sciences Inc. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. veebr 2025, 21:17 UTC

Tulu

Gilead Sciences 4Q Profit Up on HIV Product Sales, Dividend Raised

19. dets 2024, 15:25 UTC

Suurimad hinnamuutused turgudel

Assembly Biosciences Shares Rise 19% After Gilead Investment, Funding

19. dets 2024, 13:38 UTC

Suurimad hinnamuutused turgudel

Assembly Biosciences Gets $30.1 Million Equity Investment, Funding From Gilead

6. nov 2024, 22:25 UTC

Tulu

Gilead Sciences Post Higher 3Q Revenue, Raises Fiscal Year Guidance

19. märts 2025, 14:50 UTC

Peamised uudised

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

28. veebr 2025, 12:00 UTC

Peamised uudised

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

11. veebr 2025, 22:13 UTC

Market Talk
Tulu

Gilead's HIV Segment Buoying Product Sales Amid Covid Losses -- Market Talk

11. veebr 2025, 21:06 UTC

Tulu

Gilead Beats Earnings Estimates on Strong HIV Sales -- Barrons.com

11. veebr 2025, 21:02 UTC

Tulu

Gilead Sciences Planning for Potential Launch of Lenacapavir for HIV PrEP in Summer 2025>GILD

11. veebr 2025, 21:02 UTC

Tulu

Gilead Sciences Sees 2025 EPS $5.95-EPS $6.35 >GILD

11. veebr 2025, 21:02 UTC

Tulu

Gilead Sciences Raises Dividend to 79c Vs. 77c >GILD

11. veebr 2025, 21:02 UTC

Tulu

Gilead Sciences Sees 2025 Product Sales Excluding Veklury $26.8B - $27.2B>GILD

11. veebr 2025, 21:02 UTC

Tulu

Gilead Sciences Raises Dividend 2.6%>GILD

11. veebr 2025, 21:02 UTC

Tulu

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

11. veebr 2025, 21:02 UTC

Tulu

Gilead Sciences Sees 2205 Veklury Sales $1.4B>GILD

11. veebr 2025, 21:02 UTC

Tulu

Gilead Sciences Sees 2025 Sales $28.2B-$28.6B >GILD

11. veebr 2025, 21:02 UTC

Tulu

Gilead Sciences 4Q >GILD

11. veebr 2025, 21:02 UTC

Tulu

Gilead Sciences 4Q HCV Products Sales >GILD

11. veebr 2025, 21:02 UTC

Tulu

Gilead Sciences 4Q Rev Up on HIV, Oncology, Liver Disease; Partially Offset by lower sales of Veklury (Remdesivir) >GILD

11. veebr 2025, 21:02 UTC

Tulu

Gilead Sciences 4Q Adj EPS $1.90 >GILD

11. veebr 2025, 21:02 UTC

Tulu

Gilead Sciences 4Q Rev $7.57B >GILD

11. veebr 2025, 21:02 UTC

Tulu

Gilead Sciences 4Q EPS $1.42 >GILD

11. veebr 2025, 21:02 UTC

Tulu

Gilead Sciences 4Q EPS $1.42 >GILD

11. veebr 2025, 21:02 UTC

Tulu

Gilead Sciences 4Q Net $1.78B >GILD

11. veebr 2025, 21:02 UTC

Tulu

Gilead Sciences 4Q Rev $7.6B >GILD

11. veebr 2025, 21:02 UTC

Tulu

Gilead Sciences 4Q Adj EPS $1.90 >GILD

10. jaan 2025, 10:30 UTC

Peamised uudised

Trump Says World Is Free-Riding on U.S. Health Spending. He Has a Point. -- WSJ

29. dets 2024, 08:00 UTC

Omandamised, ülevõtmised, äriostud

Gilead Buys $20.1 Million of Assembly Biosciences Stock -- Barrons.com

19. dets 2024, 13:23 UTC

Suurimad hinnamuutused turgudel

Assembly Biosciences Gets $30.1M Equity Investment, Funding From Gilead

7. nov 2024, 16:23 UTC

Tulu

Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And Raise -- IBD

Võrdlus sarnastega

Hinnamuutus

Gilead Sciences Inc. Prognoos

Hinnasiht

By TipRanks

2.93% tõus

12 kuu keskmine prognoos

Keskmine 115.33 USD  2.93%

Kõrge 140 USD

Madal 90 USD

Põhineb 23 Wall Streeti analüütiku instrumendi Gilead Sciences Inc. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

23 ratings

17

Osta

6

Hoia

0

Müü

Tehniline skoor

By Trading Central

109.46 / 112.26Toetus ja vastupanu

Lühikene perspektiiv

Weak Bearish Evidence

Keskpikk perspektiiv

Neutral Evidence

Pikk perspektiiv

Weak Bullish Evidence

Sentiment

By Acuity

10 / 386 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.